MOVAPO and MOVAPO PFS are used in the treatment of Parkinson's disease to reduce the number and severity of bouts of freezing and stiffness (or “off” periods). For more information, see Section 1. Why am I using MOVAPO or MOVAPO PFS? in the full CMI. 2. What should I know before I use MOVAPO or MOVAPO PFS?

MOVAPO PFS is a pre-diluted, pre-filled syringe intended for use as a continuous infusion with a suitable pump/syringe driver. There is no need to dilute MOVAPO PFS prior to use.

MOVAPO or MOVAPO PFS contains the active ingredient apomorphine hydrochloride hemihydrate. MOVAPO and MOVAPO PFS are used in the treatment of Parkinson’s disease to reduce the number and severity of bouts of freezing and stiffness (or “off” periods).

Australian Register of Therapeutic Goods (ARTG) information for MOVAPO PFS apomorphine hydrochloride hemihydrate 50mg/10mL solution for subcutaneous infusion pre-filled syringe.

MOVAPO PFS is a pre-diluted pre-filled syringe intended for use as a continuous subcutaneous infusion with suitable pumps/syringe drivers. There is no need to dilute MOVAPO PFS prior to use.

Movapo: Apomorphine belongs to the class of medications called anti-Parkinson's agents. It is used to treat the early return of stiffness and movement problems that occur when the effects of other medications for Parkinson's disease wear off early. This "end-of-dose wearing off" of medications occurs with advanced Parkinson's disease.

Movapo® is indicated for the acute, intermitent treatment of hypomobility, “OFF episodes (“end-of-dose wearing off and unpredictable “ON/OFF” episodes) in patients with advanced Parkinson’s disease. It is an apomorphine hydrochloride injection (10 mg/mL), supplied as pre-filled pens.

MOVAPO Injection is a clear, colourless or almost colourless sterile solution for injection, practically free from visible particles with a pH of 3.0 – 4.0. MOVAPO Injection is indicated to reduce the number and severity of ‘off’ phases in patients with Parkinson’s disease severely disabled by motor fluctuations refractory to conventional therapy.

MOVAPO PFS is indicated to reduce the number and severity of "off" phases in patients with Parkinson's disease severely disabled by motor fluctuations refractory to conventional therapy.

MOVAPO POD is indicated to reduce the number and severity of ‘off’ phases in patients with Parkinson’s disease severely disabled by motor fluctuations refractory to conventional therapy. Initiation of therapy with apomorphine should be undertaken in a specialist unit in a …